These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 12112941

  • 1. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products.
    Zheng F, He C, Cai W, Hattori M, Steffes M, Vlassara H.
    Diabetes Metab Res Rev; 2002; 18(3):224-37. PubMed ID: 12112941
    [Abstract] [Full Text] [Related]

  • 2. Glomerular changes in the KK-Ay/Ta mouse: a possible model for human type 2 diabetic nephropathy.
    Ito T, Tanimoto M, Yamada K, Kaneko S, Matsumoto M, Obayashi K, Hagiwara S, Murakoshi M, Aoki T, Wakabayashi M, Gohda T, Funabiki K, Maeda K, Horikoshi S, Tomino Y.
    Nephrology (Carlton); 2006 Feb; 11(1):29-35. PubMed ID: 16509929
    [Abstract] [Full Text] [Related]

  • 3. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy.
    Shimoike T, Inoguchi T, Umeda F, Nawata H, Kawano K, Ochi H.
    Metabolism; 2000 Aug; 49(8):1030-5. PubMed ID: 10954022
    [Abstract] [Full Text] [Related]

  • 4. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice.
    Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H, Yamamoto H.
    J Clin Invest; 2001 Jul; 108(2):261-8. PubMed ID: 11457879
    [Abstract] [Full Text] [Related]

  • 5. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension.
    Busch M, Franke S, Wolf G, Brandstädt A, Ott U, Gerth J, Hunsicker LG, Stein G, Collaborative Study Group.
    Am J Kidney Dis; 2006 Oct; 48(4):571-9. PubMed ID: 16997053
    [Abstract] [Full Text] [Related]

  • 6. Increased urinary type IV collagen marks the development of glomerular pathology in diabetic d/db mice.
    Cohen MP, Lautenslager GT, Shearman CW.
    Metabolism; 2001 Dec; 50(12):1435-40. PubMed ID: 11735089
    [Abstract] [Full Text] [Related]

  • 7. Combined therapy of rhein and benazepril on the treatment of diabetic nephropathy in db/db mice.
    Jia ZH, Liu ZH, Zheng JM, Zeng CH, Li LS.
    Exp Clin Endocrinol Diabetes; 2007 Oct; 115(9):571-6. PubMed ID: 17943690
    [Abstract] [Full Text] [Related]

  • 8. Tubular atrophy, interstitial fibrosis, and inflammation in type 2 diabetic db/db mice. An accelerated model of advanced diabetic nephropathy.
    Ninichuk V, Kulkarni O, Clauss S, Anders H-.
    Eur J Med Res; 2007 Aug 16; 12(8):351-5. PubMed ID: 17933712
    [Abstract] [Full Text] [Related]

  • 9. Comparison between somatostatin analogues and ACE inhibitor in the NOD mouse model of diabetic kidney disease.
    Segev Y, Eshet R, Rivkis I, Hayat C, Kachko L, Phillip M, Landau D.
    Nephrol Dial Transplant; 2004 Dec 16; 19(12):3021-8. PubMed ID: 15494355
    [Abstract] [Full Text] [Related]

  • 10. Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice.
    Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Tesch GH.
    J Am Soc Nephrol; 2005 Jun 16; 16(6):1711-22. PubMed ID: 15857924
    [Abstract] [Full Text] [Related]

  • 11. Advanced glycosylation end products in patients with diabetic nephropathy.
    Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H.
    N Engl J Med; 1991 Sep 19; 325(12):836-42. PubMed ID: 1875967
    [Abstract] [Full Text] [Related]

  • 12. High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients.
    Cai W, He JC, Zhu L, Peppa M, Lu C, Uribarri J, Vlassara H.
    Circulation; 2004 Jul 20; 110(3):285-91. PubMed ID: 15249511
    [Abstract] [Full Text] [Related]

  • 13. Effect of varied protein intake on the nephropathy of the diabetic mouse (C57BL/s J db/db).
    Brouhard BH, Rajaraman S, LaGrone LF.
    Int J Pediatr Nephrol; 1987 Jul 20; 8(2):59-68. PubMed ID: 3308729
    [Abstract] [Full Text] [Related]

  • 14. Influence of C-peptide on early glomerular changes in diabetic mice.
    Maezawa Y, Yokote K, Sonezaki K, Fujimoto M, Kobayashi K, Kawamura H, Tokuyama T, Takemoto M, Ueda S, Kuwaki T, Mori S, Wahren J, Saito Y.
    Diabetes Metab Res Rev; 2006 Jul 20; 22(4):313-22. PubMed ID: 16389646
    [Abstract] [Full Text] [Related]

  • 15. An inhibitor of advanced glycation end product formation reduces N epsilon-(carboxymethyl)lysine accumulation in glomeruli of diabetic rats.
    Nakamura S, Tachikawa T, Tobita K, Aoyama I, Takayama F, Enomoto A, Niwa T.
    Am J Kidney Dis; 2003 Mar 20; 41(3 Suppl 1):S68-71. PubMed ID: 12612956
    [Abstract] [Full Text] [Related]

  • 16. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice.
    Tanimoto M, Gohda T, Kaneko S, Hagiwara S, Murakoshi M, Aoki T, Yamada K, Ito T, Matsumoto M, Horikoshi S, Tomino Y.
    Metabolism; 2007 Feb 20; 56(2):160-7. PubMed ID: 17224327
    [Abstract] [Full Text] [Related]

  • 17. Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711).
    Peppa M, Brem H, Cai W, Zhang JG, Basgen J, Li Z, Vlassara H, Uribarri J.
    Am J Nephrol; 2006 Feb 20; 26(5):430-6. PubMed ID: 16974073
    [Abstract] [Full Text] [Related]

  • 18. Effects of a diet rich in advanced glycation end products in the rat remnant kidney model.
    Sebeková K, Faist V, Hofmann T, Schinzel R, Heidland A.
    Am J Kidney Dis; 2003 Mar 20; 41(3 Suppl 1):S48-51. PubMed ID: 12612952
    [Abstract] [Full Text] [Related]

  • 19. Plasma glycooxidation protein products in type 2 diabetic patients with nephropathy.
    Piwowar A, Knapik-Kordecka M, Szczecińska J, Warwas M.
    Diabetes Metab Res Rev; 2008 Oct 20; 24(7):549-53. PubMed ID: 18613218
    [Abstract] [Full Text] [Related]

  • 20. The amelioration of streptozotocin diabetes-induced renal damage by Wu-Ling-San (Hoelen Five Herb Formula), a traditional Chinese prescription.
    Liu IM, Tzeng TF, Liou SS, Chang CJ.
    J Ethnopharmacol; 2009 Jul 15; 124(2):211-8. PubMed ID: 19397971
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.